Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 25.04.2022.

#Biotech
#cardiovascular
#Parkinsons
#Alzheimers
#behindthepaper

Healthcare

@BIODeutschland shared
On Apr 22, 2022
RT @CardiorPharma: Join our CEO @ClaudiaUlbrich_ next Tuesday April 26th for her panel discussion on revitalizing #cardiovascular R&D with industry colleagues at the @WuXi_AppTec Healthcare Forum. Secure your complimentary access pass here: https://t.co/go4oeaQ9g2 https://t.co/zaan3PL5DD
Open
WuXi Healthcare Forum 2022

WuXi Healthcare Forum 2022

Join thousands from around the world online this April 26-28 for the complimentary global WuXi Healthcare Forum 2022.

@SWLifeSciences shared
On Apr 19, 2022
Streetwise spoke to renowned biotech expert John Vandermosten about his 3 favorite healthcare companies addressing as-of-yet unmet market needs. Senior #Biotech Analyst's Top 3 Stocks: https://t.co/TrVOEe7V4C $ACHV $TENX $ECOR @achievelifesci @TenaxThera @ElectroCoreVNS
Open
Senior Biotech Analyst's Top 3 Stocks

Senior Biotech Analyst's Top 3 Stocks

Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies.

@SWLifeSciences shared
On Apr 19, 2022
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company. Life Sciences Co. Expected to Attract Partners, Big Pharma: https://t.co/o0f4ZoOF5T $PMN:TSX $ARFXF #biotech #Alzheimers #Parkinsons @ProMISinc
Open
Life Sciences Co. Expected to Attract Partners, Big Pharma Research Report

Life Sciences Co. Expected to Attract Partners, Big Pharma Research Report

We foresee continued execution on its developmental strategy, noted an Argus Research report.

@NatureBiotech shared
On Apr 21, 2022
@cambridgelaw @mateo_aboy Lead author @mateo_aboy goes #behindthepaper on finding that obtaining European patent protection for medical uses of known products is not a key factor limiting repurposing activity https://t.co/oHj0CLSbro
Open
European patent protection for medical uses of known products and drug repurposing

European patent protection for medical uses of known products and drug repurposing

Obtaining European patent protection for medical uses of known products is not a key factor limiting repurposing activity.

@BIODeutschland shared
On Apr 21, 2022
Viscofan BioEngineering announces Avantor as a non-exclusive distributor for their collagen research biomaterials in the U.S.A. https://t.co/LXdkJIwNNA
Open
Viscofan BioEngineering press release_070721

Viscofan BioEngineering press release_070721

1 Viscofan BioEngineering announces Avantor as a non-exclusive distributor for their collagen research biomaterials in the U.S.A. Weinheim, April 20, 2022 – Viscofan …

@matthewherper shared
On Apr 23, 2022
RT @smlungpathguy: 3. Merck is ❌! Pembrolizumab was created at Organon ✅ ! It was a small company eventually bought by Merck, which then brought this blockbuster drug to market. Funny how innovation often happens at the fringes, not in behemoths!! @kis_lorand https://t.co/FhWgjq7mMm
Open
The Startling History Behind Merck's New Cancer Blockbuster

The Startling History Behind Merck's New Cancer Blockbuster

The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly ...

Read more: Healthcare
weekly 25.04.2022
View archives
Back to home

Subscribe to Biotech - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy